pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 38 | Non-oncology: 26 Oncology: 12 |
| Under Consideration for Negotiation | 19 | Non-oncology: 8 Oncology: 11 |
| Completed Negotiations | 862 | With Letter of Intent: 749 Without agreement: 113 |
| Negotiations That Were Not Pursued | 111 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Longavo | Teva Canada Innovation | Schizophrenia in Adults | |
| Omvoh | Eli Lilly Canada Inc. | Crohn's disease | |
| Calquence | AstraZeneca Canada Inc. | In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated MCL who are ineligible for autologous stem cell transplant. | |
| Penthrox | Knight Therapeutics Inc. | Adult patients undergoing minor gynecological, ambulatory, or emergency procedures | |
| Vanflyta | Daiichi Sankyo Pharma Canada | In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid | |
| Nubeqa | Bayer Inc. | For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). | |
| Stivarga | Bayer Inc. | For the treatment of metastatic osteosarcoma in patients who received at least 1 prior line of therapy. | |
| Myfembree | Knight Therapeutics Inc. | Management of heavy menstrual bleeding associated with uterine fibroids |